BofA Securities: Maintains JD HEALTH (06618) Target Price at HK$57 and "Buy" Rating
BofA Securities stated that JD HEALTH's third-quarter revenue grew 17% year-over-year, beating expectations, and its structural growth remains intact.
BofA Securities released a research report stating that JD HEALTH (06618) experienced operational fluctuations in the third quarter, but its structural growth remains intact. The company's third-quarter revenue grew 17% year-over-year, beating expectations and improving from the 15% growth in the second quarter. The bank reiterated its "Buy" rating and maintained its target price of HK$57.
The bank remains confident that JD HEALTH's earnings are resilient and that it can benefit from economies of scale, supply chain efficiency, pharmaceutical margins, and operational efficiency, with margins expected to continue expanding. The bank also slightly lowered its 2026 earnings per share forecast from RMB2.17 to RMB2.16, and slightly raised its 2027 earnings per share forecast from RMB2.51 to RMB2.52.
Related Articles

J.P. Morgan: Maintains "Overweight" rating on Z.AI (02513), target price HK$1,200

CMBI: Raises SBP GROUP (01177) Target Price to HK$9, Maintains "Buy" Rating

Citi's Top Data Center Pick Is Equinix (EQIX.US): AI Access Points Catch Up to Seven Years of Cloud in One Year, Interconnection Networks Emerge as the Biggest Winner
J.P. Morgan: Maintains "Overweight" rating on Z.AI (02513), target price HK$1,200

CMBI: Raises SBP GROUP (01177) Target Price to HK$9, Maintains "Buy" Rating

Citi's Top Data Center Pick Is Equinix (EQIX.US): AI Access Points Catch Up to Seven Years of Cloud in One Year, Interconnection Networks Emerge as the Biggest Winner






